Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression

Cancer Cell

Volumn 6, Issue 3, 2004, Pages 297-305

  Luo, Jun Li ^a   Maeda, Shin ^a   Hsu, Li Chung ^a   Yagita, Hideo ^b   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOPTOSIS REGULATORY PROTEIN; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; TNFSF10 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL ACTIVATION; CELL STIMULATION; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEMATOPOIETIC CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CHEMICALLY INDUCED DISORDER; COLON TUMOR; ENZYME ACTIVATION; ENZYMOLOGY; INFLAMMATION; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS REGULATORY PROTEINS; COLONIC NEOPLASMS; ENZYME ACTIVATION; INFLAMMATION; LIPOPOLYSACCHARIDES; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NF-KAPPA B; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4544224979     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.08.012     Document Type: Article

References (42)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer. 2:2002;420-430
2. Ashkenazi A., Dixit V.M. Death receptors. Signaling and modulation Science. 281:1998;1305-1308
3. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:1999;155-162
4. Baldwin A.S. Jr. Series introduction. The transcription factor NF-κB and human disease J. Clin. Invest. 107:2001;3-6
5. Cao Y., Bonizzi G., Seagroves T.N., Greten F.R., Johnson R., Schmidt E.V., Karin M. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 107:2001;763-775
6. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282:1998;1714-1717
7. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867
8. Daniels J.T., Schultz G.S., Blalock T.D., Garrett Q., Grotendorst G.R., Dean N.M., Khaw P.T. Mediation of transforming growth factor-β1-stimulated matrix contraction by fibroblasts. A role for connective tissue growth factor in contractile scarring Am. J. Pathol. 163:2003;2043-2052
9. DiDonato J., Mercurio F., Rosette C., Wu-Li J., Suyang H., Ghosh S., Karin M. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol. 16:1996;1295-1304
10. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer. 4:2004;11-22
11. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting. From immunosurveillance to tumor escape Nat. Immunol. 3:2002;991-998
12. Fei P., Bernhard E.J., El-Deiry W.S. Tissue-specific induction of p53 targets in vivo. Cancer Res. 62:2002;7316-7327
13. Fogarty M.P., Downer E.J., Campbell V. A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons. Biochem. J. 371:2003;789-798
14. Ghosh S., Karin M. Missing pieces in the NF-κB puzzle. Cell. 109(Suppl.):2002;S81-S96
15. Gutterman J.U. Cytokine therapeutics. Lessons from interferon α Proc. Natl. Acad. Sci. USA. 91:1994;1198-1205
16. Harmey J.H., Bucana C.D., Lu W., Byrne A.M., McDonnell S., Lynch C., Bouchier-Hayes D., Dong Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer. 101:2002;415-422
17. Hsu L.-C., Park J.M., Zhang K., Luo J.-L., Maeda S., Kaufman R.J., Eckmann L., Guiney D.G., Karin M. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature. 428:2004;341-345
18. Karin M., Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 3:2002;221-227
19. Karin M., Cao Y., Greten F.R., Li Z.W. NF-κB in cancer. From innocent bystander to major culprit Nat. Rev. Cancer. 2:2002;301-310
20. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., Green D.R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell. 1:1998;543-551
21. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature. 411:2001;375-379
22. Makris C., Godfrey V.L., Krahn-Senftleben G., Takahashi T., Roberts J.L., Schwarz T., Feng L., Johnson R.S., Karin M. Female mice heterozygous for IKKγ/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell. 5:2000;969-979
23. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D., Innocent N., Cardiff R.D., Schnall M.D., Chodosh L.A. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2:2002;451-461
24. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B., Pasparakis M., et al. Mice deficient in tumor necrosis factor α are resistant to skin carcinogenesis. Nat. Med. 5:1999;828-831
25. Palladino M.A., Bahjat F.R., Theodorakis E.A., Moldawer L.L. Anti-TNFα therapies. The next generation Nat. Rev. Drug Discov. 2:2003;736-746
26. Pidgeon G.P., Harmey J.H., Kay E., Da Costa M., Redmond H.P., Bouchier-Hayes D.J. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br. J. Cancer. 81:1999;1311-1317
27. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 4:2004;71-78
28. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice. mutations in Tlr4 gene Science. 282:1998;2085-2088
29. Senftleben U., Li Z.W., Baud V., Karin M. IKKβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity. 14:2001;217-230
30. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., Yagita H., Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193:2001;661-670
31. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity. 18:2003;1-6
32. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., Hilliard B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191:2000;1095-1104
33. Steeg P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer. 3:2003;55-63
34. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., Iwakura Y., Yagita H., Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7:2001;94-100
35. Taketomi A., Takenaka K., Matsumata T., Shimada M., Higashi H., Shirabe K., Itasaka H., Adachi E., Maeda T., Sugimachi K. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection. Hepatogastroenterology. 44:1997;477-483
36. Tang G., Minemoto Y., Dibling B., Purcell N.H., Li Z., Karin M., Lin A. Inhibition of JNK activation through NF-κB target genes. Nature. 414:2001;313-317
37. Tracey K.J., Cerami A. Tumor necrosis factor. A pleiotropic cytokine and therapeutic target Annu. Rev. Med. 45:1994;491-503
38. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:1999;157-163
39. Wang C.Y., Cusack J.C. Jr., Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance. Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB Nat. Med. 5:1999;412-417
40. Wilson J., Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol. 12:2002;113-120
41. Wu G.S., Burns T.F., McDonald E.R. 3rd, Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:1997;141-143
42. Zhu W., Downey J.S., Gu J., Di Padova F., Gram H., Han J. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 164:2000;6349-6358